Fentanyl vs. Morphine vs. Hydromorphone: What Changes at the Bedside?
When you’re comparing opioids, give the recovery pattern as much attention as the onset. Fentanyl, morphine and hydromorphone all relieve pain mainly by activating mu opioid receptors. The differences show up in how quickly they reach the brain, where they go afterward and what happens to the drug and its metabolites. One small dose and a prolonged infusion can have very different recovery patterns.
Sachi, CRNA
CRNA

In This Article (8 sections)
- What does mu receptor activation do?
- Why does fentanyl have a faster onset than morphine?
- Does switching to hydromorphone remove the kidney concern?
- What should you compare before looking up a potency ratio?
- How can the same drug behave differently in two patients?
- Is an equianalgesic table enough for conversion?
- Our Final Thoughts
- Continue the opioid comparison
Start with the opioid lessons in the CRNA Club learning library through the seven-day platform trial. Compare the drugs by what the patient needs and what you have to watch, rather than choosing from a “strongest opioid” list.
What does mu receptor activation do?
It reduces the transmission of pain signals and changes how pain is perceived. It can also depress ventilation, reduce alertness and slow the gut. Pain relief doesn’t tell you how much of those other effects the patient is having.
A patient may look comfortable while breathing less effectively. Check ventilation and arousal as well as the pain score. An oxygen saturation doesn’t tell you how well they’re clearing carbon dioxide, especially if supplemental oxygen is keeping the saturation up.
Look at the other medications too. Additional sedatives and analgesics can increase the combined depressant effect, even when each dose looks familiar on its own.
Why does fentanyl have a faster onset than morphine?
Fentanyl dissolves readily in fat. That helps it cross into the central nervous system quickly after an IV dose. After a small single dose, some drug moves out of the brain into other tissues. That redistribution helps the effect wear off.
But what happens if fentanyl keeps coming in? With repeated doses or a prolonged infusion, drug accumulates in tissues. Recovery after stopping can take longer. A rapid onset doesn’t guarantee a rapid recovery from every infusion.
Morphine is less lipid soluble, so its central effect after an IV dose develops more slowly. Metabolites, the substances produced as the body processes morphine, become important too. The morphine prescribing information warns that clearance falls and metabolites accumulate in renal failure.
Does switching to hydromorphone remove the kidney concern?
No. Hydromorphone is another potent mu agonist, and renal impairment changes how the body handles it too. The hydromorphone prescribing information addresses adjustment and monitoring in renal impairment.
It also isn’t interchangeable with morphine milligram for milligram. Check the concentration of the actual product as well as the dose. A familiar drug name can still come in a different concentration.
Use the opioid review to compare those differences. Bring kidney and liver function, previous opioid exposure and the current respiratory assessment into the comparison before discussing a conversion.
What should you compare before looking up a potency ratio?
Ask these five questions:
- Was it one dose or sustained exposure? A long infusion changes the recovery you expect.
- Which route was used? An oral comparison doesn’t transfer directly to IV dosing.
- How are the kidneys and liver functioning? The drug or its metabolites may persist longer.
- What other depressants were given? Their effects can add to each other.
- How is the patient breathing and responding? Pain relief alone doesn’t show whether ongoing exposure is safe.
Keep those findings beside the ratio when checking the actual medication plan.
How can the same drug behave differently in two patients?
In these fictional examples, Patient A receives a small IV fentanyl dose for a brief stimulus. Patient B has had a prolonged fentanyl infusion plus other sedating medications. Calling fentanyl “short acting” doesn’t explain both recoveries. The amount stored in tissues and the other drug effects differ.
Now add Patient C, whose kidney function has declined after repeated morphine doses. They become more somnolent and their respiratory rate slows. Reassess opioid effects and metabolite accumulation while checking other causes. Changing to another opioid doesn’t remove the need to assess ventilation and the overall analgesic plan.
Is an equianalgesic table enough for conversion?
No. Equianalgesic means comparing doses expected to provide similar pain relief. The comparison depends on route, the table you’re using and the patient.
Tolerance to one opioid may not fully carry over to another. That’s incomplete cross-tolerance. Organ function and existing exposure add further uncertainty. Verify the conversion and actual product concentration through the clinical medication process instead of using a ratio from memory.
In an interview, explain how route, tolerance and clearance would change the conversion you need to verify.
Our Final Thoughts
Practice comparing one dose with sustained exposure before reaching for a potency ratio. Explain why the recovery might differ, then add the patient’s organ function and respiratory assessment. That gives you a manageable place to start without trying to memorize every conversion at once.
Continue the opioid comparison
The opioid material in the CRNA Club platform trial can support your next review. Return to the fentanyl examples, then explain what declining kidney function adds to the morphine case.


